Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human papillomavirus vaccine recombinant pentavalent
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Human papillomavirus vaccine recombinant pentavalent (V504) is a pentavalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine developed for the prevention of infection by various HPV types. Upon administration, it generates humoral immunity against several HPV L1 major capsid proteins, thereby preventing cervical and other HPV-related infections. The primary indication is the prevention of diseases caused by specific oncogenic and non-oncogenic HPV types. The developer is Merck[1][2].
- Other names
- HPV L1 VLP vaccine V504human papilloma virus L1 virus-like particle (V504) vaccine
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on Human papillomavirus vaccine recombinant pentavalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human papillomavirus vaccine recombinant pentavalent.